FDA workshop on topical antifungals and tretinoid products
Executive Summary
Scheduled for Nov. 16 from 8:30 am to 5 pm in conference room D of the FDA Parklawn Building. Participants, including experts in the field of topical anti-fungal and tretinoid products (Ortho's Retin-A) and FDA officials, will discuss proposed protocols and guidelines for bioequivalence studies for the nonsystemically asborbed products. The agency is also considering inviting reps from the Generic Pharmaceutical Industry Association, the National Association of Pharmaceutical Manufacturers, and the Pharmaceutical Manufacturers Association to provide comments. Notice of the meeting will soon appear in the Federal Register.